An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who are obese (considerably overweight) based on body mass index.

Exclusion criteria

Patients with serious or unstable current or past medical conditions

Treatment and study plan

MK0364

Drug

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Apr 25, 2005
Registry last updated: Sep 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed